NeuroGeM, a knowledgebase of genetic modifiers in neurodegenerative diseases

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  Na, Dokyun ^a,d   Rouf, Mushfiqur ^a   O'Kane, Cahir J ^b   Rubinsztein, David C ^c   Gsponer, Jörg ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Chung Ang University   (South Korea)

Author keywords

Alzheimer's disease; Database; Genetic modifiers; Huntington's disease; Knowledgebase; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

ARTICLE; ATX2 GENE; CAENORHABDITIS ELEGANS; DEGENERATIVE DISEASE; DNAJ 1 GENE; DROSOPHILA MELANOGASTER; GENE; GENE IDENTIFICATION; GENETIC DATABASE; HUMAN; MUB GENE; NEUROGEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; THREAD GENE;

CAENORHABDITIS ELEGANS; DROSOPHILA MELANOGASTER;

ANIMALS; COMPUTATIONAL BIOLOGY; DATA MINING; DATABASES, GENETIC; GENE ONTOLOGY; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84887362799     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-52     Document Type: Article

References (107)

1. Drosophila in the study of neurodegenerative disease. Marsh JL, Thompson LM, Neuron 2006 52 169 178 10.1016/j.neuron.2006.09.025 17015234 (Pubitemid 44479830)
2. Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models. Mallik M, Lakhotia SC, J Genet 2010 89 497 526 10.1007/s12041-010-0072-4 21273704
3. Drosophila models of neurodegenerative diseases. Lu B, Vogel H, Annu Rev Pathol 2009 4 315 342 10.1146/annurev.pathol.3.121806.151529 18842101
4. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Nollen EAA, Garcia SM, van Haaften G, Kim S, Chavez A, Morimoto RI, Plasterk RHA, Proc Natl Acad Sci USA 2004 101 6403 6408 10.1073/pnas.0307697101 15084750 (Pubitemid 38585986)
5. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. Bilen J, Bonini NM, PLoS Genet 2007 3 177 10.1371/journal.pgen. 0030177 (Pubitemid 350072059)
6. FlyBase. http://flybase.org/
7. WormBase. http://www.wormbase.org/
8. SGD. http://www.yeastgenome.org/
9. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q, Genome Biol 2008 9 Suppl 1 4 10.1186/gb-2008-9-s1-s4 (Pubitemid 352006138)
10. Network-based classification of breast cancer metastasis. Chuang H-Y, Lee E, Liu Y-T, Lee D, Ideker T, Mol Syst Biol 2007 3 140 17940530
11. STRING. http://string-db.org
12. GeneOntology. http://www.geneontology.org/
13. NCBI HomoloGene. http://www.ncbi.nlm.nih.gov/homologene/
14. InParanoid 7: new algorithms and tools for eukaryotic orthology analysis. Ostlund G, Schmitt T, Forslund K, Köstler T, Messina DN, Roopra S, Frings O, Sonnhammer ELL, Nucleic Acids Res 2010 38 196 D203 Database issue 10.1093/nar/gkp931 19892828
15. InParanoid. http://inparanoid.sbc.su.se/cgi-bin/index.cgi
16. EMBL (Human). ftp://ftp.ensembl.org/pub/release-68/embl/homo-sapiens/
17. HGNC. http://www.genenames.org/
18. EMBL (Mouse). ftp://ftp.ensembl.org/pub/release-68/embl/mus-musculus/
19. MGI. http://www.informatics.jax.org/
20. CytoscapeWeb. http://cytoscapeweb.cytoscape.org/
21. Genetic modifiers of tauopathy in Drosophila. Shulman JM, Feany MB, Genetics 2003 165 1233 1242 14668378 (Pubitemid 38020245)
22. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Warrick JM, Chan HYE, Gray-Board GL, Chai Y, Paulson HL, Bonini NM, Nat Genet 1999 23 425 428 10.1038/70532 10581028
23. Splice isoforms of the polyglutamine disease protein Ataxin-3 exhibit similar enzymatic yet different aggregation properties. Harris GM, Dodelzon K, Gong L, Gonzalez-Alegre P, Paulson HL, PLoS One 2010 5 13695 10.1371/journal.pone.0013695 21060878
24. Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, Eimer WA, Hitt B, Bembinster LA, Lammich S, Lichtenthaler SF, Hébert SS, De Strooper B, Haass C, Bennett DA, Vassar R, Neuron 2008 60 988 1009 10.1016/j.neuron.2008.10.047 19109907
25. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rüb U, Auburger G, Trojanowski JQ, Lee VM-Y, Deerlin VMV, Bonini NM, Gitler AD, Nature 2010 466 1069 1075 10.1038/nature09320 20740007
26. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Nishimura I, Yang Y, Lu B, Cell 2004 116 671 682 10.1016/S0092-8674(04)00170-9 15006350 (Pubitemid 38326726)
27. Aβ exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Folwell J, Cowan CM, Ubhi KK, Shiabh H, Newman TA, Shepherd D, Mudher A, Exp Neurol 2010 223 401 409 10.1016/j.expneurol.2009.09.014 19782075
28. Biological and chemical approaches to diseases of proteostasis deficiency. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE, Annu Rev Biochem 2009 78 959 991 10.1146/annurev.biochem.052308.114844 19298183
29. Molecular chaperones in protein folding and proteostasis. Hartl FU, Bracher A, Hayer-Hartl M, Nature 2011 475 324 332 10.1038/nature10317 21776078
30. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Blard O, Feuillette S, Bou J, Chaumette B, Frébourg T, Campion D, Lecourtois M, Hum Mol Genet 2007 16 555 566 10.1093/hmg/ddm011 17309878 (Pubitemid 46522618)
31. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Chan HYE, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM, Hum Mol Genet 2000 9 2811 2820 10.1093/hmg/9.19.2811 11092757
32. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Branco J, Al-Ramahi I, Ukani L, Pérez AM, Fernandez-Funez P, Rincón-Limas D, Botas J, Hum Mol Genet 2008 17 376 390 17984172
33. Genetic suppression of polyglutamine toxicity in Drosophila. Kazemi-Esfarjani P, Benzer S, Science 2000 287 1837 1840 10.1126/science.287. 5459.1837 10710314 (Pubitemid 30143971)
34. Identification of genes that modify ataxin-1-induced neurodegeneration. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She W-C, Luchak JM, Martinez P, Turiegano E, Benito J, Capovilla M, Skinner PJ, McCall A, Canal I, Orr HT, Zoghbi HY, Botas J, Nature 2000 408 101 106 10.1038/35040584 11081516
35. Identification of human proteins that modify misfolding and proteotoxicity of pathogenic Ataxin-1. Petrakis S, Raskó T, Russ J, Friedrich RP, Stroedicke M, Riechers S-P, Muehlenberg K, Möller A, Reinhardt A, Vinayagam A, Schaefer MH, Boutros M, Tricoire H, Andrade-Navarro MA, Wanker EE, PLoS Genet 2012 8 1002897 10.1371/journal.pgen.1002897 22916034
36. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY, Nat Genet 1998 19 148 154 10.1038/502 9620770 (Pubitemid 28248795)
37. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. Chai Y, Koppenhafer SL, Bonini NM, Paulson HL, J Neurosci 1999 19 10338 10347 10575031 (Pubitemid 30228041)
38. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, Sobue G, J Biol Chem 2000 275 8772 8778 10.1074/jbc.275.12.8772 10722721 (Pubitemid 30180231)
39. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Jana NR, Tanaka M, Wang G, Nukina N, Hum Mol Genet 2000 9 2009 2018 10.1093/hmg/9.13.2009 10942430 (Pubitemid 30642666)
40. A yeast two-hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brain. Long P, Samnakay P, Jenner P, Rose S, Eur J Neurosci 2012 36 2733 2742 10.1111/j.1460-9568.2012.08189.x 22779921
41. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Ghosh S, Feany MB, Hum Mol Genet 2004 13 2011 2018 10.1093/hmg/ddh214 15254017 (Pubitemid 39377825)
42. A conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible adult phenotype suitable for identifying modifier genes. Latouche M, Lasbleiz C, Martin E, Monnier V, Debeir T, Mouatt-Prigent A, Muriel M-P, Morel L, Ruberg M, Brice A, Stevanin G, Tricoire H, J Neurosci 2007 27 2483 2492 10.1523/JNEUROSCI.5453-06.2007 17344386 (Pubitemid 46393606)
43. Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons. Pugazhenthi S, Wang M, Pham S, Sze C-I, Eckman CB, Mol Neurodegener 2011 6 60 10.1186/1750-1326-6-60 21854604
44. NF-κB pathway: a target for preventing β-amyloid (Aβ)-induced neuronal damage and Aβ42 production. Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG, Ferrario M, Borsani G, Spano P, Pizzi M, Eur J Neurosci 2006 23 1711 1720 10.1111/j.1460-9568.2006.04722.x 16623827
45. Fas activation increases neural progenitor cell survival. Knight JC, Scharf EL, Mao-Draayer Y, J Neurosci Res 2010 88 746 757 19830835
46. dAtaxin-2 mediates expanded ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. Al-Ramahi I, Pérez AM, Lim J, Zhang M, Sorensen R, de Haro M, Branco J, Pulst SM, Zoghbi HY, Botas J, PLoS Genet 2007 3 234 10.1371/journal.pgen.0030234 18166084
47. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of Spinocerebellar Ataxia Type 2. Kasumu AW, Hougaard C, Rode F, Jacobsen TA, Sabatier JM, Eriksen BL, Strøbæk D, Liang X, Egorova P, Vorontsova D, Christophersen P, Rønn LCB, Bezprozvanny I, Chem Biol 2012 19 1340 1353 10.1016/j.chembiol.2012.07.013 23102227
48. ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. Damrath E, Heck MV, Gispert S, Azizov M, Nowock J, Seifried C, Rüb U, Walter M, Auburger G, PLoS Genet 2012 8 1002920 10.1371/journal.pgen.1002920 22956915
49. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PWJ, Thijs V, Dubois B, Matthijs G, van den Berg LH, Robberecht W, Neurology 2011 76 2066 2072 10.1212/WNL.0b013e31821f445b 21562247
50. ATXN2 with intermediate-length CAG/CAA repeats does not seem to be a risk factor in hereditary spastic paraplegia. Nielsen TT, Svenstrup K, Budtz-Jørgensen E, Eiberg H, Hasholt L, Nielsen JE, J Neurol Sci 2012 321 100 102 10.1016/j.jns.2012.07.036 22868089
51. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, Carvalho de M, Meyer T, Tysnes O-B O-B, Auburger G, Gispert S, Bonini NM, Andersen PM, Gitler AD, Hum Mol Genet 2011 20 1697 1700 10.1093/hmg/ddr045 21292779
52. Ataxin-2 repeat-length variation and neurodegeneration. Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, DeJesus-Hernandez M, Adamson J, Li M, Volkening K, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Woodruff BK, Knopman DS, White CL, Gerpen JAV, Meschia JF, Mackenzie IR, Boylan K, Boeve BF, Miller BL, Strong MJ, Uitti RJ, Younkin SG, Graff-Radford NR, Petersen RC, et al. Hum Mol Genet 2011 20 3207 3212 10.1093/hmg/ddr227 21610160
53. Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. Huang S, Ling JJ, Yang S, Li X-J, Li S, Brain 2011 134 Pt 7 1943 1958 21705419
54. A genomewide RNA interference screen for modifiers of aggregates formation by mutant huntingtin in Drosophila. Zhang S, Binari R, Zhou R, Perrimon N, Genetics 2010 184 1165 1179 10.1534/genetics.109.112516 20100940
55. Large-scale screen for modifiers of Ataxin-3-derived polyglutamine- induced toxicity in Drosophila. Voßfeldt H, Butzlaff M, Prüßing K, Ní Chárthaigh R-A, Karsten P, Lankes A, Hamm S, Simons M, Adryan B, Schulz JB, Voigt A, PLoS One 2012 7 47452 10.1371/journal.pone.0047452 23139745
56. Hsp105α suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity. Ishihara K, Yamagishi N, Saito Y, Adachi H, Kobayashi Y, Sobue G, Ohtsuka K, Hatayama T, J Biol Chem 2003 278 25143 25150 10.1074/jbc.M302975200 12714591 (Pubitemid 37548678)
57. Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta. Eroglu B, Moskophidis D, Mivechi NF, Mol Cell Biol 2010 30 4626 4643 10.1128/MCB.01493-09 20679486
58. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL, Hum Mol Genet 2008 17 3767 3775 10.1093/hmg/ddn273 18762557
59. Evaluation of histone deacetylases as drug targets in Huntington's disease models. Quinti L, Chopra V, Rotili D, Valente S, Amore A, Franci G, Meade S, Valenza M, Altucci L, Maxwell MM, Cattaneo E, Hersch S, Mai A, Kazantsev A, PLoS Curr 2010 Sep 2. doi: 10.1371/currents.RRN1172
60. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, Geschwind DH, Gottesfeld JM, Proc Natl Acad Sci USA 2008 105 15564 15569 10.1073/pnas.0804249105 18829438
61. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PAS, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP, Proc Natl Acad Sci USA 2003 100 2041 2046 10.1073/pnas.0437870100 12576549 (Pubitemid 36254570)
62. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM, J Neurosci 2003 23 9418 9427 14561870 (Pubitemid 37323042)
63. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. Chou CJ, Herman D, Gottesfeld JM, J Biol Chem 2008 283 35402 35409 10.1074/jbc.M807045200 18953021
64. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, H. Brown R, Ferrante RJ, J Neurochem 2005 93 1087 1098 10.1111/j.1471-4159.2005.03077.x 15934930 (Pubitemid 40776564)
65. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G, Neuropsychopharmacology 2009 35 870 880 20010553
66. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha G-H, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby LM, Peltier JM, Botas J, Hughes RE, PLoS Genet 2007 3 82 10.1371/journal.pgen.0030082 17500595 (Pubitemid 46833948)
67. Interaction of Akt-phosphorylated Ataxin-1 with 14-3-3 mediates neurodegeneration in Spinocerebellar ataxia type 1. Chen H-K, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, Aitken A, Skoulakis EMC, Orr HT, Botas J, Zoghbi HY, Cell 2003 113 457 468 10.1016/S0092-8674(03)00349-0 12757707 (Pubitemid 36588749)
68. The alternative role of 14-3-3 zeta as a sweeper of misfolded proteins in disease conditions. Kaneko K, Hachiya NS, Med Hypotheses 2006 67 169 171 10.1016/j.mehy.2006.01.019 16516399
69. Colocalization of 14-3-3 proteins with SOD1 in Lewy body-like hyaline inclusions in familial amyotrophic lateral sclerosis cases and the animal model. Okamoto Y, Shirakashi Y, Ihara M, Urushitani M, Oono M, Kawamoto Y, Yamashita H, Shimohama S, Kato S, Hirano A, Tomimoto H, Ito H, Takahashi R, PLoS One 2011 6 20427 10.1371/journal.pone.0020427 21655264
70. 14-3-3ζ is an effector of tau protein phosphorylation. Hashiguchi M, Sobue K, Paudel HK, J Biol Chem 2000 275 25247 25254 10.1074/jbc.M003738200 10840038
71. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE, Mol Biol Cell 2001 12 1393 1407 10.1091/mbc.12.5.1393 11359930 (Pubitemid 33044419)
72. Homocysteine induces apoptosis of rat hippocampal neurons by inhibiting 14-3-3 expression and activating calcineurin. Wang J, Bai X, Chen Y, Zhao Y, Liu X, PLoS One 2012 7 48247 10.1371/journal.pone.0048247 23139767
73. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein. Omi K, Hachiya NS, Tanaka M, Tokunaga K, Kaneko K, Neurosci Lett 2008 431 45 50 10.1016/j.neulet.2007.11.018 18078716
74. RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation. Doumanis J, Wada K, Kino Y, Moore AW, Nukina N, PLoS One 2009 4 7275 10.1371/journal.pone.0007275 19789644
75. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T, J Biol Chem 2008 283 26188 26197 10.1074/jbc.M710521200 18632670
76. Heat shock factor 2 is required for maintaining proteostasis against febrile-range thermal stress and polyglutamine aggregation. Shinkawa T, Tan K, Fujimoto M, Hayashida N, Yamamoto K, Takaki E, Takii R, Prakasam R, Inouye S, Mezger V, Nakai A, Mol Biol Cell 2011 22 3571 3583 10.1091/mbc.E11-04-0330 21813737
77. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. Batulan Z, Shinder GA, Minotti S, He BP, Doroudchi MM, Nalbantoglu J, Strong MJ, Durham HD, J Neurosci 2003 23 5789 5798 12843283 (Pubitemid 36807858)
78. Demyelination, astrogliosis, and accumulation of ubiquitinated proteins, hallmarks of CNS disease in hsf1-deficient mice. Homma S, Jin X, Wang G, Tu N, Min J, Yanasak N, Mivechi NF, J Neurosci 2007 27 7974 7986 10.1523/JNEUROSCI. 0006-07.2007 17652588 (Pubitemid 47173325)
79. Posttranslational modification of Ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-Terminal caspase-7 cleavage fragment. Mookerjee S, Papanikolaou T, Guyenet SJ, Sampath V, Lin A, Vitelli C, DeGiacomo F, Sopher BL, Chen SF, Spada ARL, Ellerby LM, J Neurosci 2009 29 15134 15144 10.1523/JNEUROSCI.4720-09.2009 19955365
80. Glutamine-expanded Ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. Helmlinger D, Hardy S, Abou-Sleymane G, Eberlin A, Bowman AB, Gansmüller A, Picaud S, Zoghbi HY, Trottier Y, Tora L, Devys D, PLoS Biol 2006 4 67 10.1371/journal.pbio.0040067 16494529
81. Cytosol-endoplasmic reticulum interplay by Sec61α translocon in polyglutamine-mediated neurotoxicity in Drosophila. Kanuka H, Kuranaga E, Hiratou T, Igaki T, Nelson B, Okano H, Miura M, Proc Natl Acad Sci 2003 100 11723 11728 10.1073/pnas.1934748100 14504396 (Pubitemid 37206002)
82. ERAD: the long road to destruction. Meusser B, Hirsch C, Jarosch E, Sommer T, Nat Cell Biol 2005 7 766 772 10.1038/ncb0805-766 16056268 (Pubitemid 41079045)
83. Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3. Wang Q, Li L, Ye Y, J Cell Biol 2006 174 963 971 10.1083/jcb.200605100 17000876 (Pubitemid 44455185)
84. Extremely long-lived nuclear pore proteins in the rat brain. Savas JN, Toyama BH, Xu T, Yates JR, Hetzer MW, Science 2012 335 942 942 10.1126/science.1217421 22300851
85. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. D'Angelo MA, Raices M, Panowski SH, Hetzer MW, Cell 2009 136 284 295 10.1016/j.cell.2008.11.037 19167330
86. Protein homeostasis: live long, won't prosper. Toyama BH, Hetzer MW, Nat Rev Mol Cell Biol 2013 14 55 61 23258296
87. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. Janer A, Werner A, Takahashi-Fujigasaki J, Daret A, Fujigasaki H, Takada K, Duyckaerts C, Brice A, Dejean A, Sittler A, Hum Mol Genet 2010 19 181 195 10.1093/hmg/ddp478 19843541
88. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Poukka H, Karvonen U, Jänne OA, Palvimo JJ, Proc Natl Acad Sci USA 2000 97 14145 14150 10.1073/pnas.97.26.14145 11121022 (Pubitemid 32016544)
89. SUMOylation of the polyglutamine repeat protein, Ataxin-1, is dependent on a functional nuclear localization signal. Riley BE, Zoghbi HY, Orr HT, J Biol Chem 2005 280 21942 21948 10.1074/jbc.M501677200 15824120 (Pubitemid 40827846)
90. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. Tsai YC, Fishman PS, Thakor NV, Oyler GA, J Biol Chem 2003 278 22044 22055 10.1074/jbc.M212235200 12676955 (Pubitemid 36792614)
91. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A, Orr HT, Beaudet AL, Zoghbi HY, Neuron 1999 24 879 892 10.1016/S0896-6273(00)81035-1 10624951 (Pubitemid 30017667)
92. Neurotoxin-induced selective ubiquitination and regulation of MEF2A isoform in neuronal stress response. She H, Yang Q, Mao Z, J Neurochem 2012 122 1203 1210 10.1111/j.1471-4159.2012.07860.x 22764880
93. α-synuclein aggregation reduces nigral myocyte enhancer Factor-2D in idiopathic and experimental Parkinson's disease. Chu Y, Mickiewicz AL, Kordower j, Neurobiol Dis 2011 41 71 82 10.1016/j.nbd.2010.08.022 20816781
94. Regulation of myocyte enhancer factor-2 transcription factors by neurotoxins. She H, Mao Z, Neurotoxicology 2011 32 563 566 10.1016/j.neuro.2011. 05.019 21741404
95. Anti-apoptotic wild-type Alzheimer amyloid precursor protein signaling involves the p38 mitogen-activated protein kinase/MEF2 pathway. Burton TR, Dibrov A, Kashour T, Amara FM, Brain Res Mol Brain Res 2002 108 102 120 10.1016/S0169-328X(02)00519-3 12480183 (Pubitemid 35447968)
96. Myocyte enhancing factor-2A in Alzheimer's disease: genetic analysis and association with MEF2A-polymorphisms. González P, Álvarez V, Menéndez M, Lahoz CH, Martínez C, Corao AI, Calatayud MT, Peña J, García-Castro M, Coto E, Neurosci Lett 2007 411 47 51 10.1016/j.neulet.2006.09.055 17112666 (Pubitemid 44751937)
97. Suppression of a MEF2-KLF6 survival pathway by PKA signaling promotes apoptosis in embryonic hippocampal neurons. Salma J, McDermott JC, J Neurosci 2012 32 2790 2803 10.1523/JNEUROSCI.3609-11.2012 22357862
98. Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamics. Burnett BG, Andrews J, Ranganathan S, Fischbeck KH, Di Prospero NA, Neurobiol Dis 2008 30 365 374 10.1016/j.nbd.2008.02.007 18417352
99. Proteome analysis of human substantia nigra in Parkinson's disease. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M, Proteomics 2004 4 3943 3952 10.1002/pmic.200400848 15526345 (Pubitemid 39657469)
100. Role of S5b/PSMD5 in proteasome inhibition caused by TNF-α/ NFκB in higher eukaryotes. Shim SM, Lee WJ, Kim Y, Chang JW, Song S, Jung Y-K, Cell Rep 2012 2 603 615 10.1016/j.celrep.2012.07.013 22921402
101. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Ciechanover A, Brundin P, Neuron 2003 40 427 446 10.1016/S0896-6273(03)00606-8 14556719 (Pubitemid 37244106)
102. Cellular strategies for controlling protein aggregation. Tyedmers J, Mogk A, Bukau B, Nat Rev Mol Cell Biol 2010 11 777 788 10.1038/nrm2993 20944667
103. Brain-derived neurotrophic factor in neurodegenerative diseases. Zuccato C, Cattaneo E, Nat Rev Neurol 2009 5 311 322 10.1038/nrneurol.2009.54 19498435
104. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB, Curr Biol 2006 16 230 241 16461276 (Pubitemid 43190222)
105. Upregulation of Ras homolog enriched in the brain (Rheb) in lipopolysaccharide-induced neuroinflammation. Cao M, Tan X, Jin W, Zheng H, Xu W, Rui Y, Li L, Cao J, Wu X, Cui G, Ke K, Gao Y, Neurochem Int 2013 62 406 417 10.1016/j.neuint.2013.01.025 23391520
106. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. Cheng H-C, Kim SR, Oo TF, Kareva T, Yarygina O, Rzhetskaya M, Wang C, During M, Talloczy Z, Tanaka K, Komatsu M, Kobayashi K, Okano H, Kholodilov N, Burke RE, J Neurosci 2011 31 2125 2135 10.1523/JNEUROSCI.5519-10.2011 21307249
107. Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Sang T-K, Li C, Liu W, Rodriguez A, Abrams JM, Zipursky SL, Jackson GR, Hum Mol Genet 2005 14 357 372 15590702 (Pubitemid 40227371)